6-甲基-5-氰基-4-氨基嘧啶 | 76574-44-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 6-甲基-5-氰基-4-氨基嘧啶
• 中文别名: 4-氨基-6-甲基嘧啶-5-甲腈
• 英文名称: 4-amino-6-methyl-pyrimidine-5-carbonitrile
• 英文别名: 4-Amino-6-methyl-5-cyan-pyrimidin；4-Amino-6-methylpyrimidine-5-carbonitrile
• CAS: 76574-44-2
• 化学式: C₆H₆N₄
• 分子量: 134.14
• InChiKey: HFTQOHMFCTUMHL-UHFFFAOYSA-N

物化性质

• 熔点：
  217-219 °C(Solv: ethanol (64-17-5))
• 沸点：
  345.9±42.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  75.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 安全说明：
  S24/25
• 海关编码：
  29339900
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319

反应信息

• 作为反应物：
  描述：

  6-甲基-5-氰基-4-氨基嘧啶 在 镍 甲酸 、 氢气 作用下， 反应 3.0h， 生成 4-氨基-6-甲基-5-嘧啶甲醛
  参考文献：
  名称：

  Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives

  摘要：

  A series of 51 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives was prepared and evaluated for antihypertensive activity in the conscious spontaneously hypertensive rat. A number of these compounds, notably 6-(2,6-dichlorophenyl)-2-methylpyrido[2,3-d]pyrimidin-7-amine (36), lowered blood pressure in these rats in a gradual and sustained manner to normotensive levels at oral doses of 10-50 mg/kg. Normalized blood pressure levels could then be maintained by single daily oral doses. The effect of structural variation in the 6-aryl group and in the 2 and 4 positions of the pyridopyrimidine ring on activity is reported and discussed.

  DOI：

  10.1021/jm00136a006
• 作为产物：
  描述：

  甲脒盐酸盐 、 2-(1-乙氧基亚乙基)丙二腈 在 乙醇 、 sodium 作用下， 反应 2.0h， 生成 6-甲基-5-氰基-4-氨基嘧啶
  参考文献：
  名称：

  Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives

  摘要：

  A series of 51 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives was prepared and evaluated for antihypertensive activity in the conscious spontaneously hypertensive rat. A number of these compounds, notably 6-(2,6-dichlorophenyl)-2-methylpyrido[2,3-d]pyrimidin-7-amine (36), lowered blood pressure in these rats in a gradual and sustained manner to normotensive levels at oral doses of 10-50 mg/kg. Normalized blood pressure levels could then be maintained by single daily oral doses. The effect of structural variation in the 6-aryl group and in the 2 and 4 positions of the pyridopyrimidine ring on activity is reported and discussed.

  DOI：

  10.1021/jm00136a006

文献信息

• [EN] CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION<br/>[FR] COMPOSÉS CHIMIQUES, COMPOSITIONS ET PROCÉDÉS POUR MODULATION DE KINASES
  申请人：INTELLIKINE INC

  公开号：WO2011146882A1

  公开（公告）日：2011-11-24

  Chemical compounds that modulate kinase activity, including PI3 kinase activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  本文描述了调节激酶活性的化合物，包括PI3激酶活性，以及与激酶活性相关的疾病和病况的化合物、药物组合物和治疗方法，包括PI3激酶活性。
• PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150361095A1

  公开（公告）日：2015-12-17

  The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A′, W 1 , W 2 , W 3 , R 1 , R 2 , and R 3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

  本申请提供了化合物的公式（J），或其药用盐、异构体或其混合物，其中n、m、q、A'、W1、W2、W3、R1、R2和R3如本文所述。这些化合物是磷脂酰肌醇3-激酶（PI3K）活性的抑制剂，可用于治疗由一个或多个PI3K同工型介导的疾病。本申请还提供了包括公式（J）化合物、药用盐、异构体、互变异构体或其混合物的药物组合物，以及使用这些化合物和组合物治疗由一个或多个PI3K同工型介导的疾病的方法。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Ruan Fuqiang

  公开号：US20190308963A1

  公开（公告）日：2019-10-10

  In recognition of the unmet need to develop novel therapeutic agents, the present invention discloses a novel class of heterocycles as dual inhibitors of BRD4 and class I PI3Ks. The compounds claimed herein could be used alone or in combination therapies for the effective treatment of a wide range of age-related diseases, including cancer. The present invention also provides methods for preparing compounds of the invention thereto.

  为了开发新型治疗药物的未满足需求，本发明公开了一类新型杂环化合物，作为BRD4和I类PI3Ks的双重抑制剂。本文所述的化合物可单独使用或与其他药物联合治疗，有效治疗包括癌症在内的广泛的年龄相关疾病。本发明还提供了制备这些化合物的方法。
• Tandem [3+1+1+1] Heterocyclization of α‐Acyl Ketene Dithioacetals with Ammonia and Methanol: Rapid Assembly of Polysubstituted Pyrimidines
  作者：Youkun Wang、Linlin Yan、Xiaoxuan Zhang、Fengrui Xiang、Xiaojun Li、Shengnan Li、Xiaoning Song

  DOI：10.1002/ejoc.202200237

  日期：2022.4.21

  An expeditious [3+1+1+1] heterocyclization of α-acyl ketene dithioacetals and renewable methanol as well as economical NH4OAc is established to construct densely functionalized pyrimidine derivatives. The domino conversion proceeds effectively through sequential keto imination/C−S aminolysis/cyclocondensation/dehydroaromatization processes under O2 atmosphere by harnessing the dual activities of CuCl2

  建立了 α-酰基乙烯酮二硫缩醛和可再生甲醇以及经济的 NH 4 OAc 的快速 [3+1+1+1] 杂环化，以构建密集官能化的嘧啶衍生物。通过利用CuCl 2的双重活性，即路易斯酸和脱氢，在O 2气氛下通过顺序酮亚胺化/C-S氨解/环缩合/脱氢芳构化过程有效地进行多米诺转化。
• [EN] QUINAZOLIN-4-ONE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINAZOLIN-4-ONE
  申请人：NOVARTIS AG

  公开号：WO2014128612A1

  公开（公告）日：2014-08-28

  The invention relates to quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, Formula (I) wherein R1, R2, R3, R5, R6 and L are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the class I PI3K kinases.

  该发明涉及式(I)的喹唑啉-4-酮化合物和/或其药用可接受的盐和/或溶剂，式(I)中R1、R2、R3、R5、R6和L的定义如描述中所述。这些化合物适用于治疗由I类PI3K激酶活性介导的疾病或疾病。